{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:38:53Z","timestamp":1790995133532,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jacc.2025.10.036","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:08:24Z","timestamp":1765379304000},"page":"3016-3025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Obesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6272-0666","authenticated-orcid":false,"given":"Yu Mi","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-7675","authenticated-orcid":false,"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Keech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Antonio G.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Monsalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Magnus","family":"Ohman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhui","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0691-3359","authenticated-orcid":false,"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"O\u2019Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.10.036_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 Years","volume":"377","author":"GBD Obesity Collaborators","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.10.036_bib3","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jacl.2013.04.001","article-title":"Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association","volume":"7","author":"Bays","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.10.036_bib4","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1210\/jc.2004-0372","article-title":"Obesity, metabolic syndrome, and cardiovascular disease","volume":"89","author":"Grundy","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.10.036_bib5","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.10.036_bib6","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"63","author":"Jensen","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.10.036_bib7","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.10.036_bib8","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.10.036_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.10.036_bib10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1017\/S0007114519003301","article-title":"A simple cut-off for waist-to-height ratio (0.5) can act as an indicator for cardiometabolic risk: recent data from adults in the Health Survey for England","volume":"123","author":"Gibson","year":"2020","journal-title":"Br J Nutr"},{"key":"10.1016\/j.jacc.2025.10.036_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s12889-016-2964-6","article-title":"A novel cutoff for the waist-to-height ratio predicting metabolic syndrome in young American adults","volume":"16","author":"Bohr","year":"2016","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jacc.2025.10.036_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0328760","article-title":"Is waist to height ratio better at assessing cause-specific mortality risk than body mass index or waist circumference? A prospective analysis in a large U.S.-based cohort","volume":"20","author":"Patel","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2025.10.036_bib13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.10.036_bib14","series-title":"Endotext","article-title":"Obesity and dyslipidemia","author":"Feingold","year":"2000"},{"key":"10.1016\/j.jacc.2025.10.036_bib15","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.10.036_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","article-title":"Inflammatory and cholesterol risk in the FOURIER trial","volume":"138","author":"Bohula","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.10.036_bib17","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1172\/JCI57132","article-title":"Inflammatory links between obesity and metabolic disease","volume":"121","author":"Lumeng","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacc.2025.10.036_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jacc.2025.10.036_bib19","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/S0735-1097(24)03672-6","article-title":"Cardiovascular benefit of evolocumab in 27,564 patients with and without autoimmune or inflammatory diseases: an analysis of the FOURIER trial","volume":"83","author":"Zimerman","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.10.036_bib20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/459340a","article-title":"Obesity: Causes and control of excess body fat","volume":"459","author":"Friedman","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2025.10.036_bib21","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cell.2019.03.028","article-title":"Polygenic prediction of weight and obesity trajectories from birth to adulthood","volume":"177","author":"Khera","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jacc.2025.10.036_bib22","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725100053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725100053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:43:32Z","timestamp":1780411412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725100053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":21,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0735109725100053"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.10.036","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.10.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}